Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 323 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Temozolomide & Radiation Therapy Clear all
Completed Phase 1 Interventional

PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs

NCT00385853
View directory record Official record
Conditions
Glioblastoma
Interventions
PTK787/ZK 222584, Temozolomide, Radiation Therapy
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Oct 10, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

NCT04757662
View directory record Official record
Conditions
Grade III Astrocytoma, Grade IV Astrocytoma, Astrocytoma, Grade IV, Astrocytoma, Grade III
Interventions
Tadalafil
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 10, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme

NCT00584883
View directory record Official record
Conditions
Brain Tumor
Interventions
ABT 510
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 10, 2026, 5:47 PM EDT
Recruiting Phase 2 Interventional

Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.

NCT07439172
View directory record Official record
Conditions
High Grade Gliomas, Glioblastoma, Astrocytoma, Oligodendroglioma
Interventions
Pre-radiation temozolomide.
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 10, 2026, 5:47 PM EDT
Active, not recruiting Phase 3 Interventional

Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme

NCT02685605
View directory record Official record
Conditions
Glioblastoma
Interventions
Standard surgery, Intraoperative radiotherapy, Radiochemotherapy, Temozolomide
Procedure · Radiation · Drug
Lead sponsor
Universitätsmedizin Mannheim
Other
Eligibility
18 Years to 80 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Maywood, Illinois • Lake Success, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 10, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain

NCT00012116
View directory record Official record
Conditions
Metastatic Cancer
Interventions
temozolomide
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 10, 2026, 5:47 PM EDT
Terminated Phase 1Phase 2 Interventional

Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma

NCT02046187
View directory record Official record
Conditions
Glioblastoma (GBM)
Interventions
Ketogenic Diet, Radiation therapy, Temozolomide
Dietary Supplement · Radiation · Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 10, 2026, 5:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients

NCT00402116
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
Interventions
enzastaurin, temozolomide, radiation therapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 10, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

TPI 287 in Patients With Recurrent Glioblastoma Multiforme

NCT01113463
View directory record Official record
Conditions
Brain Cancer
Interventions
TPI 287
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 10, 2026, 5:47 PM EDT
Recruiting Not applicable Interventional

REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma

NCT07831772
View directory record Official record
Conditions
Glioblastoma, Newly Diagnosed Glioblastoma, Brain Tumor
Interventions
Maintenance Radiotherapy
Radiation
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 10, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

NCT00720356
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
bevacizumab, erlotinib hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
9
States / cities
Los Angeles, California • Orlando, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 10, 2026, 5:47 PM EDT
Withdrawn Phase 2 Interventional

Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma

NCT03506139
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
External beam radiation therapy
Radiation
Lead sponsor
John M. Buatti
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 10, 2026, 5:47 PM EDT
Terminated Phase 1 Interventional

Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases

NCT00437957
View directory record Official record
Conditions
Brain Metastases
Interventions
Temozolomide, Valproic Acid, Whole Brain Radiation Therapy
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 10, 2026, 5:47 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
Drug · Radiation · Biological
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 10, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

NCT02617589
View directory record Official record
Conditions
Brain Cancer
Interventions
Nivolumab, Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 10, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional

Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy

NCT02047214
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
TPI 287, Bevacizumab
Drug
Lead sponsor
Cortice Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 10, 2026, 5:47 PM EDT
Not listed Phase 1Phase 2 Interventional

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

NCT03607643
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
Interventions
Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide
Drug
Lead sponsor
Leaf Vertical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 10, 2026, 5:47 PM EDT
Completed Early Phase 1 Interventional

Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas

NCT01678352
View directory record Official record
Conditions
High Risk WHO Grade II Glioma, Recurrent/Post-Chemotherapy WHO Grade II Glioma
Interventions
Tumor Lysate Vaccine, Imiquimod
Biological · Drug
Lead sponsor
Frank Lieberman
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 10, 2026, 5:47 PM EDT
Completed Phase 1Phase 2 Interventional

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT00662506
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
Cediranib Maleate, Diffusion Tensor Imaging, Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fludeoxyglucose F-18, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Perfusion Magnetic Resonance Imaging, Positron Emission Tomography, Temozolomide
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 10, 2026, 5:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors

NCT00441142
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma
Interventions
ZD6474, temozolomide, Radiation Therapy
Drug · Radiation
Lead sponsor
Patrick Y. Wen, MD
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
7
States / cities
Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 10, 2026, 5:47 PM EDT
Terminated Phase 1Phase 2 Interventional

Radiation Boost for Newly Diagnosed Glioblastoma Multiforme

NCT00376103
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
temozolomide, Brachytherapy, External Beam Radiation Therapy
Drug · Procedure
Lead sponsor
Methodist Healthcare - Memphis
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 18, 2009 · Synced Oct 10, 2026, 5:47 PM EDT
Withdrawn Phase 2 Interventional

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor

NCT00003273
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma, Retinoblastoma, Sarcoma
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, leucovorin calcium, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
17
States / cities
Honolulu, Hawaii • Scarborough, Maine • Grand Rapids, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 10, 2026, 5:47 PM EDT
Active, not recruiting Phase 2 Interventional

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

NCT04049669
View directory record Official record
Conditions
Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Interventions
Indoximod, Partial Radiation, Full-dose Radiation, Temozolomide, Cyclophosphamide, Etoposide, Lomustine
Drug · Radiation
Lead sponsor
Theodore S. Johnson
Other
Eligibility
3 Years to 21 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
5
States / cities
Augusta, Georgia • Druid Hills, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 10, 2026, 5:47 PM EDT
Not yet recruiting Early Phase 1 Interventional

Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas

NCT07778602
View directory record Official record
Conditions
MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma
Interventions
avutometinib and defactinib for 3 weeks on/1 week off, MGMT-unmethylated GBM with Radiation
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Atlanta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 10, 2026, 5:47 PM EDT